Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CRON vs BGM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRON Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 8–2 Matrix Metrics)

CRON Overall Winner 6-Pillar Tally: CRON 5 – 0 BGM (1 Tie) Matrix Metrics: CRON 8 – 2 BGM

As of Nov 20, 2026, Cronos Group Inc. Common Share (CRON) is the stronger overall head-to-head candidate over BGM Group Ltd. Class A (BGM) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CRON carries a Unified Composite Score of 53.4/100 (HOLD) at $3.04 (12.0x Forward P/E, 6.1% operating margin), whereas BGM carries 59.6/100 (HOLD) at $8.00 (N/M Forward P/E, -23.4% operating margin).

  • Composite vs. Pillar Nuance: While BGM currently prints a higher short-term Unified Composite Score (59.6/100 HOLD vs. CRON 53.4/100 HOLD), CRON captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (6.1% vs. -23.4% operating margin) and revenue trajectory (+74.6% vs. +69.8% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CRON vs BGM
CRON NASDAQ Head-to-Head Winner
Cronos Group Inc. Common Share
Medicinal Chemicals & Botanical Products
$3.04
-1.3% 1D
Market Cap $1.1B
TTM Revenue $206M
Forward P/E 12.0x
Beta / 30D Vol 0.36β · 38% Vol
Unified Composite Score
53.4 / 100 HOLD
Tech 27.0 Fund 47.0 Flow 58.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 34
RSI-14: 33.9 · SMA20: $3.36 · SMA50: $3.32
BGM NASDAQ
BGM Group Ltd. Class A Ordinary Shares
Pharmaceutical Preparations
$8.00
-1.6% 1D
Market Cap $108.6M
TTM Revenue $48M
Forward P/E N/M
Beta / 30D Vol 3.69β · 80% Vol
Unified Composite Score
59.6 / 100 HOLD
Tech 65.0 Fund 55.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (167.7% over 20 days), RSI 54
RSI-14: 53.8 · SMA20: $8.51 · SMA50: $5.25

6-Pillar Scorecard Institutional Category Breakdown (CRON 5 – 0 BGM)

Columns: Metric · CRON · BGM
1. Valuation Multiples CRON
Forward P/E 12.0x N/M
Trailing P/E 19.2x N/M
PEG Ratio N/M N/M
EV / Revenue 3.5x 2.3x
2. Growth & Scale CRON
Revenue Growth (YoY) +74.6% +69.8%
Earnings Growth (YoY) -44.7% +0.0%
TTM Revenue (USD) $206M $48M
Market Cap $1.1B $108.6M
3. Profitability & Quality CRON
Gross Margin 46.3% 16.9%
Operating Margin 6.1% -23.4%
Net Profit Margin 28.0% -44.2%
Return on Equity (ROE) 6.1% -7.4%
4. Balance Sheet & Cash Flow CRON
Cash Generation (TTM) $65M -$9.2M EBITDA
Cash Flow Margin 31.6% -19.3% EBITDA Mgn
Net Cash / Leverage $410M Net Cash $59.55 Book/Sh · -7.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CRON
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 45.3% (20th %ile) N/A (N/A)
Put/Call OI Skew 0.01x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity 40.2% of Rev ($83M) 40.3% of Rev ($19M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CRON (8) vs BGM (2)
Institutional Metric CRON BGM Criterion Row Edge
Market Capitalization
Scale
$1.1B $108.6M Larger Scale CRON
Trailing P/E Ratio
Valuation
19.2x N/M Lower Multiple CRON
Forward P/E Ratio
Valuation
12.0x N/M Lower Multiple CRON
Revenue Growth (YoY)
Growth
+74.6% +69.8% Higher Growth CRON
Operating Margin (TTM)
Profitability
6.1% -23.4% Higher Margin CRON
Net Profit Margin
Profitability
28.0% -44.2% Higher Margin CRON
Return on Equity (ROE)
Capital Efficiency
6.1% -7.4% Higher ROE CRON
52-Week Range Position
Momentum
47% ($2–$4) 74% ($0–$11) Stronger Trend BGM
Beta / 30D Volatility
Risk Regime
0.36β · 38% Vol 3.69β · 80% Vol Lower Realized Risk CRON
Unified Institutional Score
Composite Signal
53.4 / 100 (HOLD) 59.6 / 100 (HOLD) Higher Composite BGM
Trailing 12M Revenue (USD)
Operating Scale
$206M $48M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
46.3% 16.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.5x EV/Rev N/M PEG · 2.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$65M ($410M Net Cash) -$9.2M EBITDA ($59.55 Book/Sh · -7.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CRON +17.52 pp
CRON: -4.05% · BGM: -21.57%
3M Horizon BGM +2676.77 pp
CRON: -2.84% · BGM: +2673.93%
6M Horizon BGM +2951.6 pp
CRON: +11.19% · BGM: +2962.79%
1Y Horizon CRON +36.28 pp
CRON: +30.51% · BGM: -5.77%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRON vs BGM. Trailing 12-month operating profitability (CRON 6.1% vs BGM -23.4%) and valuation multiples (CRON 12.0x vs BGM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CRON ADR TTM Benchmark FX-Normalized USD
TTM Revenue$206M
Gross Margin46.3%
Op. Margin6.1%
ROE / Fwd P/E6.1% · 12.0x
BGM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$48M
Gross Margin16.9%
Op. Margin-23.4%
ROE / Fwd P/E-7.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CRON CONSOLIDATION
61d in phase · OBV DISTRIBUTION
Current IV 45.3%
IV Percentile 20th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CRON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BGM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BGM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CRON Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $1.1B market capitalization and 6.1% operating margin.
OpEx & R&D Reinvestment 40.2% of Rev ($83M)
90D Engineering Disclosures 0 Published
BGM Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $108.6M market capitalization and -23.4% operating margin.
OpEx & R&D Reinvestment 40.3% of Rev ($19M)
90D Engineering Disclosures 0 Published

Investor FAQ CRON vs BGM Key Questions & Quantitative Answers

As of Nov 20, 2026, Cronos Group Inc. Common Share (CRON) is the stronger overall head-to-head candidate over BGM Group Ltd. Class A (BGM) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CRON carries a Unified Composite Score of 53.4/100 (HOLD) at $3.04 (12.0x Forward P/E, 6.1% operating margin), whereas BGM carries 59.6/100 (HOLD) at $8.00 (N/M Forward P/E, -23.4% operating margin). Composite vs. Pillar Nuance: While BGM currently prints a higher short-term Unified Composite Score (59.6/100 HOLD vs. CRON 53.4/100 HOLD), CRON captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (6.1% vs. -23.4% operating margin) and revenue trajectory (+74.6% vs. +69.8% YoY).

CRON leads the Growth & Scale pillar: CRON posts +74.6% YoY revenue growth and -44.7% YoY earnings growth on $206M TTM revenue (46.3% gross margin, 6.1% operating margin), compared with BGM at +69.8% YoY revenue growth and +0.0% YoY earnings growth on $48M TTM revenue (16.9% gross margin, -23.4% operating margin). On trailing 12-month operating scale, CRON generates $206M in USD-normalized revenue versus $48M for BGM. In operating R&D and SG&A reinvestment, CRON deploys 40.2% of Rev ($83M) (0 90-day corporate R&D disclosures) versus 40.3% of Rev ($19M) (0 disclosures) for BGM.

CRON screens cheaper on headline valuation multiples. CRON trades at 12.0x Forward P/E, 19.2x Trailing P/E, N/M PEG, and 3.5x EV/Revenue (31.6% FCF margin), whereas BGM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.3x EV/Revenue (-19.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRON (6.1% ROE) versus BGM (-7.4% ROE) capital efficiency.

In options market volatility and institutional positioning, CRON carries 45.3% implied volatility (20th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.36β · 38% Vol realized risk). By comparison, BGM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.69β · 80% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.